HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Telfer, P. Articles by Kirkham, F. Search for Related Content PubMed PubMed Citation Articles by Telfer, P. Articles by Kirkham, F.

Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London

From the Department of Paediatric Haematology and Oncology, Royal London Hospital, London (PT, JE, DR, SC, OW); Infection Control Office, The Windeyer Institute of Medical Science, University College, University of London (PC); Sickle and Thalassaemia Centre, London (BS); Department of Haematology, Homerton Hospital, Homerton Row, London (RA, AS); Neurosciences Unit, Wolfson Centre, London, UK (FK)

Correspondence: Paul Telfer, Department of Haematology Royal London Hospital, Whitechapel Road, London E1 1BB, UK. E-mail paul.telfer{at}bartsandthelondon.nhs.uk

Background and Objectives: We investigated outcomes in a UK neonatal cohort as a benchmark for care of children with sickle cell disease (SCD).

Design and Methods: Two-hundred and fifty-two children (180 with hemoglobin [Hb] SS, 64 with HbSC, and 8 with HbS/ß thalassemia), identified during 1983–2005 by universal birth screening in East London, were followed in a hospital and community-based program which included penicillin V prophylaxis from 3 months of age, 23-valent pneumococcal polysaccharide vaccine from 1993, conjugate pneumococcal vaccine from 2002 and transcranial Doppler screening from 1991.

Results: At the end of 2005, there were 2158 patient years of observation. The median age of the patients was 7.8 (interquartile range 3.3–13.0) years, and 2.8% of those enrolled had been lost to follow-up. The estimated survival of children with HbSS at 16 years was 99.0% (95% confidence interval, CI, 93.2 to 99.9%) and pneumococcal sepsis rate was 0.3 (95% CI 0.1–0.8) episodes per 100 patient-years. The risk of overt stroke was 4.3% (95%CI 1.5 to 11.4%) and could be further reduced by transcranial Doppler screening from infancy and transfusing all children with high-risk scans. No deaths, strokes or episodes of pneumococcal sepsis were observed in children with HbSC or HbS/ß thalassemia. The mortality rates from HbSS were significantly lower than those in other reported cohorts.

Interpretation and Conclusions: Mortality in childhood SCD can virtually be eliminated in a well-resourced health service setting linking community-based care with a specialized, hospital-based center. SCD continues to cause substantial morbidity from acute complications and chronic organ damage. We recommend setting up of clinical networks to optimize the management of SCD.

Key words: neonatal screening, sickle cell, mortality, infection, cerebrovascular disorders.

This article has been cited by other articles:

				I. Roberts and M. de Montalembert Sickle cell disease as a paradigm of immigration hematology: new challenges for hematologists in Europe Haematologica, July 1, 2007; 92(7): 865 - 871. [Full Text] [PDF]